Beximco Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Beximco Pharmaceuticals has a total shareholder equity of BDT53.6B and total debt of BDT4.5B, which brings its debt-to-equity ratio to 8.4%. Its total assets and total liabilities are BDT70.9B and BDT17.3B respectively. Beximco Pharmaceuticals's EBIT is BDT8.5B making its interest coverage ratio 7.9. It has cash and short-term investments of BDT1.7B.
Key information
8.4%
Debt to equity ratio
৳4.51b
Debt
| Interest coverage ratio | 7.9x |
| Cash | ৳1.74b |
| Equity | ৳53.60b |
| Total liabilities | ৳17.30b |
| Total assets | ৳70.90b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BXP's short term assets (BDT22.5B) exceed its short term liabilities (BDT9.3B).
Long Term Liabilities: BXP's short term assets (BDT22.5B) exceed its long term liabilities (BDT8.0B).
Debt to Equity History and Analysis
Debt Level: BXP's net debt to equity ratio (5.2%) is considered satisfactory.
Reducing Debt: BXP's debt to equity ratio has reduced from 37.2% to 8.4% over the past 5 years.
Debt Coverage: BXP's debt is well covered by operating cash flow (163.1%).
Interest Coverage: BXP's interest payments on its debt are well covered by EBIT (7.9x coverage).